Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

← Back to our analysis

Original News Release

Tempramed Technologies releases VIVI Med

Mr. Ron Nagar reports TEMPRAMED LAUNCHES NEW PRODUCT "VIVI MED," UNLOCKING NEW GROWTH OPPORTUNITIES IN HIGH-VALUE BIOLOGICS AND INJECTABLE MEDICATIONS Tempramed Technologies Ltd. has launched commercially VIVI Med, a new temperature-protection solution designed to safeguard medication vials, biologics and other critical therapies that fall outside the insulin-pen format. The launch of VIVI Med provides significant expansion of the company's total addressable market opportunity, by extending its proven thermal-protection technology into new drug categories, broader patient populations and higher-value use cases. By addressing medications such as GLP-1 receptor agonists, biologics including Humira, insulin vials, injectable medication vials and temperature-sensitive blood glucose test strips, VIVI Med substantially increases the scope of the company's commercial reach. As the global use of biologics, GLP-1 therapies and specialty injectables continues to grow across chronic, autoimmune and metabolic conditions, the need for reliable, portable and power-free temperature protection is becoming increasingly critical. VIVI Med is engineered to provide 24/7/365 passive protection for years -- without batteries, charging or maintenance-supporting real-world use across travel, work and active lifestyles. "To date, our product portfolio has focused on insulin pens and epinephrine auto-injectors, but the medication landscape is evolving rapidly," said Ron Nagar, chief executive officer of Tempramed. "VIVI Med is a strategic expansion of our platform that allows us to address a much broader universe of temperature-sensitive medications, many of which are high-value biologics with growing patient populations. This product materially expands our addressable market and creates new opportunities across consumer, B2B and health-care-system channels. Using our proprietary, patented technology, we will continue to expand our product portfolio with new products, new applications and new markets." Key features of VIVI Med Expanded compatibility: designed for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors and temperature- and light-sensitive glucose test strips; Year-round temperature protection: Maintains safe medication temperatures without refrigeration, electricity or maintenance; Portable and lifestyle-friendly: compact, lightweight, reusable design for daily use, travel and outdoor environments Durable, long-life construction: built with space-grade materials and engineered for years of repeated use. Strategic and commercial significance With the introduction of VIVI Med, Tempramed now offers a multiformat temperature-protection platform spanning: VIVI Cap and VIVI Cap Smart for insulin pens and certain GLP-1 pens; VIVI Epi for epinephrine auto-injectors; VIVI Med for vials, biologics, GLP-1 pens, test strips and broader injectable formats. About Tempramed Technologies Ltd. Tempramed Technologies is a global leader in innovative, temperature-controlled medication storage solutions. We seek Safe Harbor.
View at source ↗